You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 119 No. 11, November 1983 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ARTICLES
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (35)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Cutaneous Pigmentation Secondary to Amiodarone Therapy

James W. Trimble, MD; Deborah S. Mendelson, MD; Bernard F. Fetter, MD; Peter Ingram, PhD; John J. Gallagher, MD; John D. Shelburne, MD, PhD

Arch Dermatol. 1983;119(11):914-918.


Abstract



• Amiodarone (Cordarone) is an iodinated cardiac antiarrhythmic drug that causes a slate-gray discoloration of the sun-exposed skin and a yellow-brown stippling of the cornea. Histopathologically, biopsy specimens of aminodarone pigmentation sites disclose yellow-brown refractile granules in the reticular dermis. These granules were characterized by transmission electron microscopy as being concentrically arranged intralysosomal inclusions ("myelinlike" bodies) in dermal endothelial cells and perivascular smooth-muscle cells. Electron probe x-ray analysis of these same inclusions disclosed definite peaks for iodine, evidence for the presence of amiodarone or a metabolite of the drug at these sites. Amiodarone, then, concentrates in lysosomes and causes an accumulation of lipids similar to what has been seen with other cationic amphiphilic compounds, such as the glycosphingolipid stored in Fabry's disease. Amiodarone must be recognized as a cause of a drug-induced lipid storage disease with cutaneous and corneal manifestations.

(Arch Dermatol 1983;119:914-918)



Author Affiliations



From the Divisions of Dermatology (Dr Trimble) and Cardiology (Dr Gallagher), Department of Medicine and the Department of Pathology (Drs Mendelson, Fetter, and Shelburne), Duke University and Veterans Administration Medical Centers, Durham, NC; and the Division of Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, NC (Dr Ingram).


Footnotes



Accepted for publication Dec 24, 1982.

Reprint requests to Department of Pathology, Duke University Medical Center, Box 3712, Durham, NC 27710 (Dr Shelburne).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cutaneous Manifestations of Adverse Drug Reactions
West and Rumsfield
Journal of Pharmacy Practice 1989;2:251-255.
ABSTRACT  

Microprobe Analysis of Chlorpromazine Pigmentation
Benning et al.
Arch Dermatol 1988;124:1541-1544.
ABSTRACT  

Dermatologic Problems in the Intensive Care Unit: Part IV
Berman and Silvestri
J Intensive Care Med 1986;1:224-239.
ABSTRACT  

Toxic Epidermal Necrolysis and Amiodarone Treatment
Bencini et al.
Arch Dermatol 1985;121:838-838.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1983 American Medical Association. All Rights Reserved.